Ligandability Assessment of IL-1β by Integrated Hit Identification Approaches.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
10 May 2024
Historique:
medline: 10 5 2024
pubmed: 10 5 2024
entrez: 10 5 2024
Statut: aheadofprint

Résumé

Human interleukin-1β (IL-1β) is a pro-inflammatory cytokine that plays a critical role in the regulation of the immune response and the development of various inflammatory diseases. In this publication, we disclose our efforts toward the discovery of IL-1β binders that interfere with IL-1β signaling. To this end, several technologies were used in parallel, including fragment-based screening (FBS), DNA-encoded library (DEL) technology, peptide discovery platform (PDP), and virtual screening. The utilization of distinct technologies resulted in the identification of new chemical entities exploiting three different sites on IL-1β, all of them also inhibiting the interaction with the IL-1R1 receptor. Moreover, we identified lysine 103 of IL-1β as a target residue suitable for the development of covalent, low-molecular-weight IL-1β antagonists.

Identifiants

pubmed: 38728572
doi: 10.1021/acs.jmedchem.4c00240
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Anna Vulpetti (A)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Jean-Michel Rondeau (JM)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Marie-Hélène Bellance (MH)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Jutta Blank (J)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Ralf Boesch (R)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Andreas Boettcher (A)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Frédéric Bornancin (F)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Sylvia Buhr (S)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Lauren E Connor (LE)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Christoph E Dumelin (CE)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Oliver Esser (O)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Michael Hediger (M)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Samuel Hintermann (S)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Ulrich Hommel (U)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Elke Koch (E)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Guillaume Lapointe (G)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Lukas Leder (L)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Sylvie Lehmann (S)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Philipp Lehr (P)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Peter Meier (P)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Lionel Muller (L)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Daniela Ostermeier (D)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Paul Ramage (P)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Sihame Schiebel-Haddad (S)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Alexander Baxter Smith (AB)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Aleksandar Stojanovic (A)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Juraj Velcicky (J)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Rina Yamamoto (R)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Konstanze Hurth (K)

Biomedical Research, Novartis, CH-4002 Basel, Switzerland.

Classifications MeSH